Sep 24, 2021 / 02:00PM GMT
Operator
Good morning, and welcome to the KOL webinar focused on the novel DYRK1A target and its role in autoimmunity hosted by Brickell Biotech. (Operator Instructions) As a reminder, this webinar is being recorded, and a replay will be made available on the Brickell Biotech website following the conclusion of the event.
Turning to Slide 2. This presentation contains forward-looking statements. Please reference this slide and our recent SEC filings for additional disclosures of risks and uncertainties. I would now like to turn the call over to Dr. Monica Luchi, Brickell's Chief Medical Officer, for a brief introduction.
Monica E. Luchi - Brickell Biotech, Inc. - Chief Medical Officer
Thank you, Sarah. I'd like to thank everyone for joining the call today. We'll go to the next slide, please.
Homeostasis, or balance of the immune system, is the ideal in healthy individuals. When that balance is disrupted, excess inflammation, sometimes against self, may result. Inhibition of DYRK1A enhances regulatory T cell differentiation and decreases MyD88 and IRAK4
Brickell Biotech Inc Key Opinion Leader Webinar on DYRK1A Transcript
Feb 13, 2024
Already have an account? Log in
Get the full story
| Access to All Earning Calls and Stock Analysis | |
| 30-Year Financial on one screen | |
| All-in-one Stock Screener with unlimited filters | |
| Customizable Stock Dashboard | |
| Real Time Insider Trading Transactions | |
| 8,000+ Institutional investors’ 13F holdings | |
| Powerful Excel Add-in and Google sheets Add-on | |
| All data downloadable | |
| Quick customer support | |
| And much more... |
30-Day 100% money back guarantee
You are not charged until the trial ends. Subscription fee may be tax deductible.
Excellent 
4.6 out of 5 
Trustpilot
Trustpilot
Survey
We'd love to learn more about your experiences on GuruFocus.com and how we can improve!
Take Survey
Follow Us
Disclaimers